Maryland：Ozempic 和 GLP-1 诉讼 | DrugsMonitor.com

Ozempic 和 GLP-1 诉讼在 Maryland (MD) 中：案卷时代的案件入门、关键的法律截止日期和今天的机密审查请求，而不是法律建议。

索马鲁肽、替泽帕肽、Wegovy、Mounjaro、Rybelsus、胃轻瘫、肠梗阻, Maryland

Residents of Maryland (MD) who used medications such as Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs sometimes explore whether their injuries overlap with allegations raised in national litigation. Filing deadlines, medical causation, and where a case may proceed are fact-specific questions for qualified counsel in Maryland and in the federal MDL, not for a website overview.

Products and reported injury patterns

GLP-1 agonists—including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda)—mimic a hormone that affects insulin and appetite. They have helped many patients meet glycemic or weight goals, but a subset of users have reported debilitating stomach and intestinal problems.

Litigation pleadings and media coverage have highlighted diagnoses such as severe gastroparesis (stomach paralysis), ileus or bowel obstruction, persistent vomiting, and emergency interventions. Allegations in civil complaints often include failure to warn and related product-liability theories. Regulatory agencies have issued or updated safety communications as post-marketing data accumulated; regulatory action is separate from private lawsuits.

马里兰州 context

协调一致的 MDL 实践塑造了 Ozempic 和 GLP-1 诉讼 的共同发现，但 马里兰州 读者通常仍然就 MD 报关、医疗记录访问和任何并行的国家行动如何符合他们自己的时间顺序提出建议。

西部地区的旅行距离、法院积压案件和当地专家市场各不相同； 马里兰州 客户有时会首先以数字方式合并记录，因为 MD 围绕 HIPAA 授权的做法可能会减慢纸张提取速度。